First dose in HERACLES clinical trial Part Two
Filed with ASX · · 3 pages · English
Sydney, 17 November 2025: Clinical-stage biotech company Noxopharm Limited (ASX:NOX) is pleased to announce the first dosing has been administered in the second part of the HERACLES clinical trial. HERACLES is a first-in-human trial for SOF-SKN™, a novel drug candidate for autoimmune diseases. The double-blind and placebo-controlled Phase I trial aims to evaluate the safety and tolerability profil
In the deck
Story so far
Earlier from Noxopharm
- Second part of HERACLES clinical trial begins
- September 2025 Quarterly Activities Report and Appendix 4C
- First US patent for Sofra technology platform
- Extension of Convertible Notes and Funding
- HERACLES clinical trial Update 4
Later from Noxopharm
- HERACLES clinical trial Update 5
- HERACLES clinical trial successfully completed
- December 2025 Quarterly Activities Report and Appendix 4C
- Sofra breakthrough science publish in major medical journal
- At-the-Market (ATM) agreement with Acuity Capital
Follow Noxopharm into a list and get an email when it puts out news.
Follow Noxopharm